1. Introduction
===============

Fluoropyrimidines (FPs), which include 5-fluorouracil (5-FU) and its oral prodrugs S-1, capecitabine, and tegafur-uracil (UFT), have been prescribed for various malignancies involved in the gastrointestinal tract, breast, head and neck, and ovaries.^\[[@R1]--[@R3]\]^ Common adverse events of FPs include bone marrow toxicities, anorexia, diarrhea, mucositis, and hand-foot syndrome. Acute hyperammonemic encephalopathy secondary to FPs is a rare complication that generally occurs after infusion of high-dose 5-FU, and its pathophysiology remains unclear. The incidence of encephalopathy induced by 5-FU has been reported to be 5.7% to 8.7% among patients treated with high dose of 5-FU infusion (2600 mg/m^2^ over 24 hours, every week).^\[[@R4],[@R5]\]^ As for currently used regimens, including intermediate dose of 5-FU infusion or oral FP, this toxicity has been described only in case reports or case series.^\[[@R6]--[@R16]\]^ Hence, incidence and optimal management are not fully understood. Most cases completely and rapidly recover, but clinical features in some cases can be fatal.^\[[@R15]--[@R17]\]^ Therefore, it is important for clinicians to recognize this complication early and treat appropriately. The aim of this study was to estimate the incidence of hyperammonemic encephalopathy and to characterize the clinical manifestations in cancer patients who developed hyperammonemic encephalopathy after receiving widely used FP-based chemotherapy.

2. Methods
==========

2.1. Patients
-------------

We retrospectively reviewed a computerized database of 1786 patients with gastrointestinal or primary-unknown cancer who had locally advanced and/or metastatic lesions and received FP-based regimens at the Aichi Cancer Center Hospital between January 2007 and December 2012. FP antitumor drugs included 5-FU, S-1, capecitabine, and UFT. Among these patients, we identified patients who developed acute hyperammonemic encephalopathy after receiving FP-based chemotherapies. This study was approved by the Institutional Review Board at Aichi Cancer Center Hospital.

2.2. Definitions
----------------

Acute hyperammonemic encephalopathy was diagnosed according to previously reported criteria: development of encephalopathy during or shortly after completion of FPs administration; exclusion of other metabolic or physical factors that may have an effect on the consciousness level; and exclusion of a drug effect by concomitant medications.^\[[@R4]\]^ Additionally, patients with hepatic failure due to liver metastases or coexisting liver cirrhosis were excluded.

2.3. Data collection
--------------------

Patient demographics obtained from medical records were as follows: the Eastern Cooperative Oncology Group performance status (ECOG PS), primary tumor location, histology, chemotherapeutic regimen, time from the start of chemotherapy to onset of encephalopathy, and survival time. Data on infection, dehydration, constipation, renal dysfunction, and muscle loss, which were proposed as risk factors for hyperammonemic encephalopathy by Liaw et al^\[[@R6]\]^ and Kikuta et al^\[[@R10]\]^ were also collected. Status of patients was evaluated at the time of the initiation of course when patients developed encephalopathy. Muscle loss was evaluated using the skeletal muscle index (SMI), which was calculated via a previously described method using a cross-sectional computed tomography image of the third lumbar vertebra (L3).^\[[@R18]\]^ Patients were considered to have sarcopenia, a status of skeletal muscle loss, when SMI was lower than 34.9 cm^2^/m^2^ for women and 40.8 cm^2^/m^2^ for men.^\[[@R19]\]^ Encephalopathy was assessed by depressed level of consciousness (Common Terminology Criteria for Adverse Events version 4.0). Survival was defined as the time from the diagnosis of hyperammonemic encephalopathy to death. Probabilities for survival were determined using the Kaplan--Meier method.

3. Results
==========

3.1. Patients
-------------

Of the 1786 patients, 1176 (65.8%), 679 (38.0%), 255 (14.3%), and 39 (2.2%) patients received 5-FU, S-1, capecitabine, and UFT, respectively. None of the patients received infusion 5-FU on a high-dose schedule (\>2000 mg/m^2^ over 24 hours). Primary tumor sites were as follows: colorectal (n = 723), gastric (n = 618), esophageal (n = 361), unknown (n = 55), anal (n = 16), and small bowel (n = 13). Hyperammonemic encephalopathy occurred in 13 patients (0.7%) during chemotherapy. Of them, 2 patients were excluded for the following reasons: each patient had hepatic failure due to multiple liver metastases and multiple liver metastases with coexisting alcoholic cirrhosis, respectively. Accordingly, 11 patients (0.6%) were identified as developing acute hyperammonemic encephalopathy. The incidence according to the administered anticancer drugs were as follows: 5-FU (8 of 1176, 0.7%), S-1 (1 of 679, 0.1%), capecitabine (2 of 225, 0.9%), and UFT (0 of 39, 0%).

The baseline patient characteristics are shown in Table [1](#T1){ref-type="table"}. The median age was 62 years (range: 38--75). All patients had metastatic lesions. Five patients (45.5%) had poor PS (ECOG PS ≥2). The rate of occurrence by primary site was as follows: gastric (5 of 618, 0.8%), colorectal (4 of 723, 0.6%), esophagus (1 of 361, 0.3%), and unknown primary (1 of 55, 1.8%). Seven patients (63.6%) had received at least 1 other regimen before. Among these patients, all 7 patients received another regimen containing FPs, and 3 patients had previously received a regimen containing the same FP agent. Ten patients (90.9%) had at least 1 predisposing factor: all except 1 were diagnosed with sarcopenia.
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3.2. Clinical course
--------------------

The clinical courses for the 11 patients are shown in Table [2](#T2){ref-type="table"}. Three patients developed encephalopathy during the first cycle of the regimen and the remaining 8 patients during the second or more cycles. Median time to the onset of hyperammonemic encephalopathy in the cycle was 3 days (range: 2--21). While the onset of symptoms was observed during or shortly after exposure to FPs for 9 patients, 2 patients who received oral FP agents developed encephalopathy on days 15 and 21 of the cycle, respectively. Median time from initiation of first-line chemotherapy to the onset was 567 days (range: 3--1169). Case 10 developed encephalopathy in the 26th cycle of simplified LV5FU2 after 978 days from the initiation of regimen. All the patients presented with altered mental status: 2 patients (18.1%) developed Grade 1 depressed consciousness; 6 patients (54.5%) developed Grade 2; and 3 patients (27.2%) developed Grade 3. The median level of serum ammonia was 253 μg/dL (range: 213--\> 400).
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Treatment and clinical courses.
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If administration of FPs was ongoing, chemotherapy was stopped immediately. Adequate fluid infusion, including branched-chain amino acids, was administrated for all patients, and 4 patients took lactulose orally. Immediate improvement of symptoms was obtained, followed by normalization of ammonia levels within 1 week. After the improvement of symptoms, 6 patients (Cases 2, 3, 5, 8, 9, and 10) resumed chemotherapy and best supportive care was selected for the remaining 5 patients. Among the 6 patients who received chemotherapy, 3 patients (Cases 8, 9, and 10) continued the same regimen after recovery from encephalopathy. Cases 9 and 10 were successfully managed with 50% dose reduction of 5-FU continuous infusion until disease progression. Case 8 continued the same dose of capecitabine as symptoms were relatively mild. Although mild hyperammonemic encephalopathy recurred with slightly elevated level of serum ammonia and dose reduction of capecitabine was performed eventually, a total of 8 cycles were delivered until disease progression. Case 3, who had developed encephalopathy due to S-1 monotherapy, received modified FOLFOX-6 without encephalopathy later. The median overall survival time after hyperammonemic encephalopathy was 4.3 months (Fig. [1](#F1){ref-type="fig"}). Although most patients died soon after the development of acute hyperammonemic encephalopathy, 3 patients, all of whom had resumed chemotherapy, survived for more than 1 year.

![Kaplan--Meier curves are shown for overall survival after hyperammonemic encephalopathy.](medi-96-e6874-g003){#F1}

4. Discussion
=============

In this study, we identified 1786 patients treated with widely used FP-based chemotherapies over the study period, with acute hyperammonemic encephalopathy occurring in 11 (0.6%). The overall incidence was much lower than that reported for patients on high-dose 5-FU (5.7% and 8.7%, respectively).^\[[@R4],[@R5]\]^ This is probably explained by the dose of 5-FU. In the study by Liaw et al,^\[[@R6]\]^ high daily dose of 5-FU (1800  or 2600 mg/m^2^) was significantly associated with higher plasma ammonia levels and more rapid onset of hyperammonemic encephalopathy (mean: 3.2 vs 1.1 days, *P*\<.0001) compared with a low daily dose (500 or 1000 mg/m^2^). Our finding also highlights the importance of recognizing this toxicity even in the use of oral FP agents. Intriguingly, the estimated incidence in S-1 (0.1%) appeared lower than that in 5-FU infusion (0.7%). This difference may be attributable to the effect of dihydropyrimidine dehydrogenase inhibition that usually leads to the decrease of 5-FU catabolites.

Although the precise mechanism of hyperammonemic encephalopathy remains to be fully understood, it was proposed by Koenig and Patel^\[[@R20]\]^ that fluoroacetate, one of the catabolites of 5-FU, directly suppresses the Krebs cycle and in turn causes dysfunction in the ATP-dependent urea cycle, leading to transient accumulation of ammonium. In general, ammonium produced through 5-FU catabolism itself does not cause hyperammonemia, but infection, dehydration, constipation, and renal dysfunction aggravate this condition.^\[[@R6]\]^ In addition, body weight loss accompanied by muscle atrophy can promote accumulation of ammonium as the skeletal muscle is an important site of ammonia catabolism.^\[[@R10]\]^ Most of the patients in our cohort had at least 1 predisposing factor similar to factors outlined in previous reports,^\[[@R6],[@R8]--[@R11],[@R15]\]^ and all 7 patients in our study with a previous exposure to FPs experienced no episode of encephalopathy. It is noteworthy that most of patients (90.9%) met the definition of sarcopenia. Although body mass index was also examined, 7 patients (63.6%) were within normal limits (18.5--\< 22.5). Previous reports concluded that sarcopenia is associated with toxicities of chemotherapy.^\[[@R21]--[@R24]\]^ Our results suggested that sarcopenia can also be a predictive marker for the development of hyperammonemic encephalopathy. The majority of patients distinctively had multiple lines of therapies and poor ECOG PS, resulting in worse prognosis.

Our findings were similar to those in previous reports on 5-FU-induced encephalopathy with respect to the time to onset and the time to recovery. All patients developed encephalopathy during or shortly after 5-FU exposure (range: 2--6 days) and recovered with the decrease of serum ammonia within 3 days after immediate discontinuation of FPs and supportive therapies, consistent with existing reports.^\[[@R6]--[@R9],[@R12]\]^ In a large cohort study of 29 patients with 5-FU-related encephalopathy, the time to onset ranged from 0.5 to 5 days.^\[[@R6]\]^ Most of the patients recovered within 2 days, but 4 patients with infection remained comatose. In this study, bacterial infection was associated with higher plasma ammonium concentrations and more rapid onset of hyperammonemia^\[[@R6]\]^; therefore, no comorbid infectious disease in our series may account for the observed good prognosis. The number of cycles or lines at the onset of encephalopathy varied. Of the 11 patients, only 4 (36.3%) experienced the events at the first exposure to the FP drug. Among 3 patients receiving oral FP agents, 2 developed encephalopathy on days 21 and 15 of the cycle. Kwon et al^\[[@R14]\]^ reported a case of hyperammonemic encephalopathy developed 14 days after the completion of 5-FU infusion. Therefore, clinicians should be aware of this entity whenever FP-containing regimens are continued despite the number of cycles or lines of chemotherapy.

There is a lack of reliable data informing and providing guidance for alternative treatments for patients experiencing FP-associated encephalopathy. In some reports, reducing the dose of infusion 5-FU or exchanging it with capecitabine chemotherapy was successfully done without recurrence.^\[[@R7]--[@R9]\]^ In the study by Liaw et al,^\[[@R6]\]^ 7 of 29 patients received the same regimen after treating hyperammonemic encephalopathy without recurrence. In our series, 3 patients (27.3%) received another 2 or more cycles of the same regimen with dose reduction and were successfully re-challenged. One patient with a previous history of encephalopathy due to S-1 monotherapy continued modified FOLFOX-6 therapy successfully. Regarding continuing chemotherapy, not only the re-challenge of the same regimen with dose reduction but also switching to another FPs regimen can be a reasonable option.

There are several limitations in our study. First, it was difficult to confirm whether patients developed hyperammonemic encephalopathy as a result of FPs only. Five patients (45.4%) received a regimen in combination with oxaliplatin. However, there are some reports regarding FP-induced hyperammonemic encephalopathy, while there is only 1 case report that was suspected to develop hyperammonemic encephalopathy due to oxaliplatin use.^\[[@R25]\]^ Second, we did not check the level of ammonia in all patients who received FPs. Patients with mild symptoms could be overlooked, and the incidence may be underestimated. However, this is the first systematic report to show the clinical features of FP-induced hyperammonemic encephalopathy in currently used FP-based regimens despite these limitations.

In summary, acute hyperammonemic encephalopathy is rare but warrants much attention given the toxicity of FP-based chemotherapy, which remains to be the treatment cornerstone of various solid cancers. Clinicians should be aware of this entity in every treatment cycle and even in the administration of oral FP agents, especially in the presence of possible predisposing factors. Nonetheless, this complication can be effectively treated due to early detection and proper management.

Abbreviations: 5-FU = 5-fluorouracil, ECOG PS = Eastern Cooperative Oncology Group performance status, FP = fluoropyrimidine, L3 = third lumbar vertebra, SMI = skeletal muscle index, UFT = tegafur-uracil.
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